Epidermal Growth Factor Receptor Mutations
Epidermal Growth Factor Receptor Mutations
复制标题
DOI：
10.1016/j.thorsurg.2020.01.008
复制
发表时间：
2020-05-01
影响因子：
2.1
通讯作者：
Gentzler, Ryan D.
中科院分区：
文献类型：
--
作者：
McLoughlin, Erin M.;Gentzler, Ryan D.
在美国和欧洲，高达20%的肺腺癌和亚洲的50%具有表皮生长因子受体（EGFR）的酪氨酸激酶结构域的激活突变。EGFR-酪氨酸激酶抑制剂（TKI）的突变的鉴定和随后的靶向治疗导致EGFR突变肺癌的治疗取得了重大进展。新一代EGFR-TKI改善了结局，毒副作用更少，耐受性更好。对EGFR-TKI的耐药性仍然是一个重要的障碍，需要更好地了解耐药机制。目前正在努力将靶向治疗纳入早期疾病患者的治疗。
Up to 20% of lung adenocarcinomas in the United States and Europe and 50% in Asia have activating mutations of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). The identification and subsequent targeting of mutations with EGFR-tyrosine kinase inhibitors (TKIs) led to significant advances in treatment of EGFR-mutant lung cancer. Newer-generation EGFR-TKIs resulted in improvement in outcomes, with less toxic side effects and better tolerability. Resistance to EGFR-TKIs remains a significant barrier, and better understanding of resistance mechanisms is needed. Efforts are ongoing to incorporate targeted therapy into treatment of patients with earlier-stage disease.